title: Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye.
abstract: OBJECTIVE
  To evaluate the efficacy of cyclosporine 0.05% (CsA) eye drops in patients with Stevens Johnson syndrome (SJS) who had chronic dry eye.
  
  
  METHODS
  Prospective noncomparative interventional case series.
  
  
  METHODS
  Thirty cases of SJS patients who developed dry eye defined by symptoms and signs, including the Schirmer I test, the fluorescein clearance test (FCT), and corneal staining (fluorescein and Rose Bengal staining) were treated with CsA 0.05% eye drops twice daily for 6 months. Dry eye symptoms, eye injection, tear break up time (TBUT), and corneal staining were evaluated before and after the treatment at 0, 2, 4, and 6 months. The Shirmer I test and FCT were evaluated at 0 and 6 months.
  
  
  RESULTS
  Seventeen patients (56.67%) completed the study. Eight patients (26.67%) withdrew from the study as a result of intolerable side effects of CsA, which included pain, redness, and eyelid swelling. Five cases were lost in follow up. All 17 cases demonstrated significant improvement in dry eye symptoms, conjunctival injection, corneal staining, Schirmer I test, and FCT (P<0.05).
  
  
  CONCLUSIONS
  CsA 0.05% eye drops might be beneficial in the treatment of chronic dry eye associated with SJS.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. pinnita.t@gmail.com
authors.forename: Pinnita
authors.initials: P
authors.lastname: Prabhasawat
authors.forename: Nattaporn
authors.initials: N
authors.lastname: Tesavibul
authors.forename: Chulavech
authors.initials: C
authors.lastname: Karnchanachetanee
authors.forename: Sirilux
authors.initials: S
authors.lastname: Kasemson
mesh_terms: D060433:Administration, Ophthalmic; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013262:Stevens-Johnson Syndrome / Q000150:complications*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine